Jak2 V617F Mutation Detection

JAK2 V617F Mutation Detection

What it is

The JAK2 V617F Mutation Detection test identifies a specific mutation in the JAK2 (Janus kinase 2) gene, where valine (V) is replaced by phenylalanine (F) at position 617. This mutation is the most common genetic marker in myeloproliferative neoplasms (MPNs), occurring in over 95% of patients with polycythemia vera (PV) and in about 50–60% of those with essential thrombocythemia (ET) or primary myelofibrosis (PMF).

Uses

This test is used to diagnose and classify MPNs such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. It also helps distinguish these blood cancers from secondary causes of elevated blood counts. Additionally, it can assist in monitoring disease progression and evaluating response to targeted therapy.

Symptoms That May Lead to the Test

Doctors may recommend this test if you have persistently high red blood cell, white blood cell, or platelet counts. Symptoms prompting testing include headaches, dizziness, itching (especially after warm showers), enlarged spleen, night sweats, unexplained blood clots, or unusual bleeding.

Abnormal Results

Positive for JAK2 V617F Mutation: Strongly suggests the presence of a myeloproliferative neoplasm such as PV, ET, or PMF. Further diagnostic tests may be required to classify the exact condition.

Negative Result: Indicates that the V617F mutation is not present. However, other mutations such as JAK2 Exon 12, CALR, or MPL may still be responsible for MPN symptoms, so additional testing may be recommended.

Risks

The test is performed on a blood sample, with minimal risks such as mild pain, bruising, or dizziness at the puncture site. In some cases, bone marrow testing may also be suggested for a complete evaluation.